The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

John Abraham

School of Social Sciences

University of Sussex

Arts E Building Falmer

Brighton BN19QN

United Kingdom

[email]@sussex.ac.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • School of Social Sciences, University of Sussex, Arts E Building Falmer, Brighton BN19QN, United Kingdom. 2010
  • Department of Sociology, Centre for Research in Health and Medicine, University of Sussex, Falmer, UK. 2002 - 2009
  • Centre for Research in Health and Medicine, Department of Sociology, School of Social Sciences and Cultural Studies, University of Sussex, UK. 2006 - 2008
  • Department of Sociology, University of Sussex, Brighton, UK. 1998 - 2008

References

  1. On the prohibition of conflicts of interest in pharmaceutical regulation: precautionary limits and permissive challenges. A commentary on Sismondo (66:9, 2008, 1909-14) and O'Donovan and Lexchin. Abraham, J. Soc. Sci. Med (2010) [Pubmed]
  2. Drug evaluation and the permissive principle: continuities and contradictions between standards and practices in antidepressant regulation. Abraham, J., Davis, C. Soc. Stud. Sci (2009) [Pubmed]
  3. Global health challenges in the pharmaceutical world. Abraham, J. Health. Economics,. Policy,. Law (2009) [Pubmed]
  4. The politics and bio-ethics of regulatory trust: case-studies of pharmaceuticals. Abraham, J. Med. Health. Care. Philos (2008) [Pubmed]
  5. Sociology of pharmaceuticals development and regulation: a realist empirical research programme. Abraham, J. Sociol. Health. Illn (2008) [Pubmed]
  6. Testing times: the emergence of the practolol disaster and its challenge to British drug regulation in the modern period. Abraham, J., Davis, C. Soc. Hist. Med (2006) [Pubmed]
  7. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy. Abraham, J., Davis, C. Soc. Sci. Med (2005) [Pubmed]
  8. Pharmaceuticals, the state and the global harmonisation process. Abraham, J. Aust. Health. Rev (2004) [Pubmed]
  9. The science and politics of medicines control. Abraham, J. Drug. Saf (2003) [Pubmed]
  10. Reshaping the carcinogenic risk assessment of medicines: international harmonisation for drug safety, industry/regulator efficiency or both?. Abraham, J., Reed, T. Soc. Sci. Med (2003) [Pubmed]
  11. Progress, innovation and regulatory science in drug development: the politics of international standard-setting. Abraham, J., Reed, T. Soc. Stud. Sci (2002) [Pubmed]
  12. Transnational industrial power, the medical profession and the regulatory state: adverse drug reactions and the crisis over the safety of Halcion in the Netherlands and the UK. Abraham, J. Soc. Sci. Med (2002) [Pubmed]
  13. The pharmaceutical industry as a political player. Abraham, J. Lancet (2002) [Pubmed]
  14. Regulatory science as culture: contested two-dimensional values at the US FDA. Abraham, J. Sci. Cult. (Lond) (2002) [Pubmed]
  15. Harmonising and competing for medicines regulation: how healthy are the European Union's systems of drug approval?. Abraham, J., Lewis, G. Soc. Sci. Med (1999) [Pubmed]
  16. Rethinking transparency and accountability in medicines regulation in the United Kingdom. Abraham, J., Sheppard, J., Reed, T. BMJ (1999) [Pubmed]
  17. Secrecy and transparency of medicines licensing in the EU. Abraham, J., Lewis, G. Lancet (1998) [Pubmed]
 
WikiGenes - Universities